# Basal-bolus Insulin Therapy Versus Standard Therapy for the Inpatient Management of Type 2 Diabetes: the IDA2 Study

> **NCT03244241** · PHASE4 · UNKNOWN · sponsor: **Merete Bechmann Christensen** · enrollment: 100 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Insulin Degludec 100 UNT/ML [Tresiba]

## Key facts

- **NCT ID:** NCT03244241
- **Lead sponsor:** Merete Bechmann Christensen
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-04-01
- **Primary completion:** 2018-04-01
- **Final completion:** 2018-04-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2017-08-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03244241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03244241, "Basal-bolus Insulin Therapy Versus Standard Therapy for the Inpatient Management of Type 2 Diabetes: the IDA2 Study". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03244241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*